FDA: Discontinued Strength for IV Antibiotic Used for Serious Pneumonia

250mg per vial strength being discontinued
250mg per vial strength being discontinued

The Food and Drug Administration (FDA) is reporting that Vibativ (telavancin; Theravance) 250mg per vial strength is being discontinued. The affected product has NDC#62847-002-01. 

Vibativ is indicated for the treatment of adults with complicated skin and skin structure infections due to susceptible gram (+) bacteria. It is also approved to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/HAVP) due to Staphylococcus aureus when alternative treatments are not suitable.

Related Articles

Vibativ in the 750mg per vial strength will continue to be available. 

Telavancin, a lipoglycopeptide antibiotic, inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II. Telvancin also binds to the bacterial membrane and disrupts membrane barrier function.

For more information call (855) 784-7972 or visit Vibativ.com.